JP2017515837A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515837A5 JP2017515837A5 JP2016567370A JP2016567370A JP2017515837A5 JP 2017515837 A5 JP2017515837 A5 JP 2017515837A5 JP 2016567370 A JP2016567370 A JP 2016567370A JP 2016567370 A JP2016567370 A JP 2016567370A JP 2017515837 A5 JP2017515837 A5 JP 2017515837A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antagonist
- taa
- agonist
- immunogenic combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461992788P | 2014-05-13 | 2014-05-13 | |
| US61/992,788 | 2014-05-13 | ||
| PCT/US2015/029855 WO2015175334A2 (en) | 2014-05-13 | 2015-05-08 | Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017515837A JP2017515837A (ja) | 2017-06-15 |
| JP2017515837A5 true JP2017515837A5 (enExample) | 2018-06-14 |
| JP6747981B2 JP6747981B2 (ja) | 2020-08-26 |
Family
ID=53499070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016567370A Active JP6747981B2 (ja) | 2014-05-13 | 2015-05-08 | 腫瘍抗原発現組換えポックスウイルス及び免疫チェックポイント分子アンタゴニストまたはアゴニストを用いた癌治療のための併用療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20170266270A1 (enExample) |
| EP (1) | EP3142690B1 (enExample) |
| JP (1) | JP6747981B2 (enExample) |
| KR (1) | KR102499737B1 (enExample) |
| CN (1) | CN106456747A (enExample) |
| AU (1) | AU2015259510B2 (enExample) |
| CA (1) | CA2946418C (enExample) |
| DK (1) | DK3142690T3 (enExample) |
| ES (1) | ES2913236T3 (enExample) |
| IL (1) | IL248507B (enExample) |
| NZ (1) | NZ725459A (enExample) |
| RU (1) | RU2724433C2 (enExample) |
| WO (1) | WO2015175334A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| ES2833425T3 (es) * | 2014-07-16 | 2021-06-15 | Roussy Inst Gustave | Combinación de virus oncolítico con moduladores de punto de control inmunitario |
| EP4523756A3 (en) * | 2015-02-13 | 2025-05-28 | Transgene | Immunotherapeutic vaccine and antibody combination therapy |
| CN115300622A (zh) | 2015-02-25 | 2022-11-08 | 纪念斯隆-凯特琳癌症中心 | 使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合 |
| CN107847534B (zh) | 2015-04-17 | 2022-10-04 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| IL261321B2 (en) | 2016-02-25 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| KR20180133395A (ko) | 2016-02-25 | 2018-12-14 | 메모리얼 슬로안 케터링 캔서 센터 | 암 면역요법을 위한, 인간 flt3l 또는 gm-csf의 발현이 있거나 없으며 티미딘 키나제가 결실된 복제 가능 약독화 백시니아 바이러스 |
| CN109312364A (zh) * | 2016-03-18 | 2019-02-05 | 河谷细胞有限公司 | 用于感染树突状细胞的多模式载体 |
| EP3225253A1 (en) * | 2016-04-01 | 2017-10-04 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor |
| CN107281474A (zh) * | 2016-04-11 | 2017-10-24 | 中国科学院上海巴斯德研究所 | 增强抗肿瘤免疫反应的新型免疫策略和免疫组合物 |
| EP4253419A3 (en) | 2016-06-02 | 2024-05-22 | Ultimovacs ASA | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
| HRP20211703T1 (hr) * | 2016-11-02 | 2022-02-04 | Jounce Therapeutics, Inc. | Protutijela protiv pd-1 i njihova upotreba |
| KR200486872Y1 (ko) | 2016-11-16 | 2018-07-10 | 김영선 | 가변형 조립식 책상 |
| WO2018209315A1 (en) | 2017-05-12 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| WO2018234506A2 (en) | 2017-06-21 | 2018-12-27 | Transgene Sa | PERSONALIZED VACCINE |
| CN111050790B (zh) * | 2017-08-24 | 2024-07-12 | 巴法里安诺迪克有限公司 | 通过静脉内施用重组mva和抗体治疗癌症的组合疗法 |
| US20210177964A1 (en) * | 2017-11-06 | 2021-06-17 | Memorial Sloan Kettering Cancer Center | Heat-inactivated vaccinia virus as a vaccine immune adjuvant |
| US20190367568A1 (en) * | 2018-02-05 | 2019-12-05 | Nantbio, Inc. | Calreticulin and fusion proteins |
| TWI905535B (zh) | 2018-04-23 | 2025-11-21 | 美商南特細胞公司 | 新抗原表位疫苗及免疫刺激組合物及方法 |
| US11564980B2 (en) | 2018-04-23 | 2023-01-31 | Nantcell, Inc. | Tumor treatment method with an individualized peptide vaccine |
| MX2021003013A (es) | 2018-09-15 | 2021-08-11 | Memorial Sloan Kettering Cancer Center | Poxvirus recombinantes para inmunoterapia contra cáncer. |
| CA3119503A1 (en) * | 2018-11-20 | 2020-05-28 | Bavarian Nordic A/S | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CA3133971A1 (en) * | 2019-03-20 | 2020-09-24 | Turnstone Biologics Inc. | Sequential heterologous boost oncolytic viral mmunotherapy |
| US20230405105A1 (en) | 2019-09-20 | 2023-12-21 | Transgene Sa | Combination of a poxvirus encoding hpv polypeptides with an anti-pd-l1 antibody |
| CR20220220A (es) | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| IL293012A (en) * | 2019-11-20 | 2022-07-01 | Bavarian Nordic As | Medicinal uses of 4-1bbl modified ankara virus vaccinia ((recombinant mva |
| US20230190922A1 (en) * | 2019-11-20 | 2023-06-22 | Bavarian Nordic A/S | Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1119354A (en) * | 1914-01-05 | 1914-12-01 | Adelbert Armstrong | Broom-holder. |
| US1391972A (en) * | 1920-08-05 | 1921-09-27 | American Cotton Oil Company | Method and apparatus for molding soap |
| DK2439273T3 (da) * | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
-
2015
- 2015-05-08 KR KR1020167030977A patent/KR102499737B1/ko active Active
- 2015-05-08 CN CN201580034007.8A patent/CN106456747A/zh active Pending
- 2015-05-08 AU AU2015259510A patent/AU2015259510B2/en active Active
- 2015-05-08 DK DK15733563.9T patent/DK3142690T3/da active
- 2015-05-08 JP JP2016567370A patent/JP6747981B2/ja active Active
- 2015-05-08 EP EP15733563.9A patent/EP3142690B1/en active Active
- 2015-05-08 RU RU2016148311A patent/RU2724433C2/ru active
- 2015-05-08 WO PCT/US2015/029855 patent/WO2015175334A2/en not_active Ceased
- 2015-05-08 CA CA2946418A patent/CA2946418C/en active Active
- 2015-05-08 IL IL248507A patent/IL248507B/en unknown
- 2015-05-08 US US15/310,405 patent/US20170266270A1/en not_active Abandoned
- 2015-05-08 ES ES15733563T patent/ES2913236T3/es active Active
- 2015-05-08 NZ NZ725459A patent/NZ725459A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017515837A5 (enExample) | ||
| RU2016148311A (ru) | Комбинированная терапия для лечения рака с помощью рекомбинантного поксвируса, экспрессирующего опухолевый антиген, и антагониста или агониста молекулы иммунной контрольной точки | |
| JP2017515841A5 (enExample) | ||
| JP2016537417A5 (enExample) | ||
| RU2016122035A (ru) | Комбинированное лекарственное средство для лечения рака с использованием поксвируса, экспрессирующего опухолевый антиген, и антагониста и/или агониста ингибитора имунной контрольной точки | |
| JP7368305B2 (ja) | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ－３に対するモノクローナル抗体を用いた癌治療のための併用療法 | |
| Lee et al. | DNA vaccines, electroporation and their applications in cancer treatment | |
| Tobias et al. | Vaccination against Her-2/neu, with focus on peptide-based vaccines | |
| JP2022507744A5 (enExample) | ||
| Chang et al. | Vaccinating against cancer: getting to prime time | |
| JP2023503857A5 (enExample) | ||
| JP2019517508A5 (enExample) | ||
| JP2024105526A (ja) | 免疫応答を誘導するための組成物 | |
| FI3463436T3 (fi) | Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää | |
| CN108699128A (zh) | 恶性病变的组合治疗 | |
| Bhagat et al. | CEA vaccines | |
| Kraynyak et al. | Tapping the potential of DNA delivery with electroporation for cancer immunotherapy | |
| PH12020500194A1 (en) | Malaria vaccine | |
| Kim et al. | Phase 2 trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, in patients with metastatic, refractory renal cell carcinoma (RCC) | |
| US20180028630A1 (en) | Compositions and methods for therapeutic anti-cancer vaccination | |
| Friedlaender et al. | A new generation of vaccines in the age of immunotherapy | |
| NZ759184B2 (en) | Methods of treating bladder cancer | |
| JP2017531699A5 (enExample) | ||
| NZ759184A (en) | Methods of treating bladder cancer | |
| Dakappagari et al. | Evaluation of synergistic interaction between cytokines and peptide epitope vaccines in protection against HER-2 expressing lung metastases |